Maha Alaa El Din Abd El Fatah

Publications

• Research Article   
  Neoadjuvant Modified FOLFIRINOX Regimen followed by Stereotactic Body Radiation Therapy (SBRT) in Non-Metastatic Pancreatic Adenocarcinoma
  Author(s): Maha Alaa El Din Abd El Fatah*, Mostafa Mahmoud El Serafi, Hanan Ramadan Nassar, Fouad Abd El Shahed Fouad and Yasser Anwar Abd Al Azim
  
  Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with a 5-year survival of approximately 10%. Most patients present with advanced disease, and only 10–20% have resectable tumors at diagnosis. As surgery remains the only potentially curative treatment, neoadjuvant therapy aims to improve resectability and identify treatment failures early. Multidisciplinary management is essential for borderline resectable and locally advanced PDAC. Objectives: To evaluate neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) for four months followed by stereotactic body radiotherapy (SBRT) in non-metastatic, borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC), focusing on resectability, progression-free survival (PFS), overall survival (OS), toxicity, and prognostic factors. Methods: This single-arm prospective phase II trial included 28 patie.. Read More»
  

  Abstract HTML PDF